NCT05733351 2025-09-15Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate CancerEmory UniversityPhase 1 Terminated4 enrolled
NCT03770455 2024-07-09Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPCTulane UniversityPhase 2 Terminated8 enrolled 7 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT02758132 2019-11-08Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone MetastasesUniversity of HawaiiPhase 2 Terminated1 enrolled 7 charts
NCT01741753 2019-02-05BKM120+Abiraterone Acetate for Metastatic CRPCDana-Farber Cancer InstitutePhase 1 Terminated4 enrolled
NCT01828476 2017-05-04Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate CancerRutgers, The State University of New JerseyPhase 2 Terminated13 enrolled 5 charts